Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Filippo De Marinis; Alain Vergnenegre; Antonio Passaro; Catherine Dubos-Arvis; Enric Carcereny; Ana Drozdowskyj; Ali Zeaiter; Pablo Perez-Moreno; Rafael Rosell

doi:10.2217/fon.14.269

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Filippo De Marinis, Alain Vergnenegre, Antonio Passaro, Catherine Dubos-Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Perez-Moreno, Rafael Rosell

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

Original language	English
Pages (from-to)	421-429
Number of pages	9
Journal	Future Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.2217/fon.14.269
Publication status	Published - Feb 1 2015

Keywords

EGFR
erlotinib
non-small-cell lung cancer
rash
safety

ASJC Scopus subject areas

Oncology
Cancer Research
Medicine(all)

Access to Document

10.2217/fon.14.269

Cite this

@article{af93267c2f1a46379d3fa9c6c1cc3ae9,

title = "Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial",

abstract = "Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.",

keywords = "EGFR, erlotinib, non-small-cell lung cancer, rash, safety",

author = "{De Marinis}, Filippo and Alain Vergnenegre and Antonio Passaro and Catherine Dubos-Arvis and Enric Carcereny and Ana Drozdowskyj and Ali Zeaiter and Pablo Perez-Moreno and Rafael Rosell",

year = "2015",

month = feb,

day = "1",

doi = "10.2217/fon.14.269",

language = "English",

volume = "11",

pages = "421--429",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

AU - De Marinis, Filippo

AU - Vergnenegre, Alain

AU - Passaro, Antonio

AU - Dubos-Arvis, Catherine

AU - Carcereny, Enric

AU - Drozdowskyj, Ana

AU - Zeaiter, Ali

AU - Perez-Moreno, Pablo

AU - Rosell, Rafael

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

AB - Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

KW - EGFR

KW - erlotinib

KW - non-small-cell lung cancer

KW - rash

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84923093517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923093517&partnerID=8YFLogxK

U2 - 10.2217/fon.14.269

DO - 10.2217/fon.14.269

M3 - Article

C2 - 25675123

AN - SCOPUS:84923093517

VL - 11

SP - 421

EP - 429

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this